-
1.发明申请7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders 审中-公开7-磺酰基-3-苯并吖庚因衍生物作为多巴胺受体的调节剂及其用于治疗cns病症的用途公开(公告)号：US20050176759A1
公开(公告)日：2005-08-11
申请号：US10499776
申请日：2002-12-20
申请人： Mahmood Ahmed , Steven Bromidge , Ian Forbes , Andrew Gribble , Christopher Johnson , Francis King , Andrew Lightfoot , Gregor Macdonald , Stephen Moss , Mervyn Thompson , David Witty
发明人： Mahmood Ahmed , Steven Bromidge , Ian Forbes , Andrew Gribble , Christopher Johnson , Francis King , Andrew Lightfoot , Gregor Macdonald , Stephen Moss , Mervyn Thompson , David Witty
IPC分类号： C07D223/14 , A61K31/55 , A61P1/08 , A61P3/04 , A61P15/00 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , C07D223/16 , C07D401/12 , C07D403/12 , A61K31/47 , A61K31/4035
CPC分类号： C07D223/16 , C07D401/12 , C07D403/12
摘要： Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
摘要翻译： 发明的是非肽TPO模拟物。 还发明了一种在有需要的哺乳动物（包括人）中治疗血小板减少症的方法，其包括向所述哺乳动物施用有效量的选择的羟基-1-偶氮苯衍生物。
-
2.发明申请7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders 审中-公开具有5ht6受体亲和力的7-芳基磺酰胺基-2,3,4,5-四氢-1h-苯并二氮杂衍生物用于补偿cns病症公开(公告)号：US20050090485A1
公开(公告)日：2005-04-28
申请号：US10503678
申请日：2003-02-13
IPC分类号： A61K31/40 , A61K31/47 , A61K31/55 , A61P3/04 , A61P25/06 , A61P25/08 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , C07D209/44 , C07D217/02 , C07D217/04 , C07D223/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
CPC分类号： C07D223/16 , A61K31/40 , A61K31/47 , A61K31/55 , C07D209/44 , C07D217/02 , C07D217/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要： The present invention relates to novel sulfonamide compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
摘要翻译： 本发明涉及具有药理学活性的新型磺酰胺化合物，其制备方法，含有它们的组合物及其在治疗CNS和其它疾病中的用途。
-
3.发明申请3-((Hetero)arylsulfonyl)-8-'(aminoalkyl)oxyquinolines as 5-ht6 receptor antagonists for the treatment of cns disorders 审中-公开3 - （（杂芳基）芳基磺酰基）-8 - （氨基烷基）氧喹啉作为治疗cns病症的5-ht6受体拮抗剂公开(公告)号：US20070191345A1
公开(公告)日：2007-08-16
申请号：US10599002
申请日：2005-03-24
IPC分类号： A61K31/55 , A61K31/5377 , A61K31/4709 , A61K31/4704 , C07D413/02 , C07D401/02
CPC分类号： C07D215/36 , C07D401/12 , C07D405/12 , C07D413/12 , C07D453/02
摘要： The present invention relates to novel quinoline derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of CNS and other disorders.
摘要翻译： 本发明涉及新的喹啉衍生物，例如式（I）的化合物：以及这些化合物或其药物组合物在治疗CNS和其它病症中的用途。
-
公开(公告)号：US20060287334A1
公开(公告)日：2006-12-21
申请号：US10571405
申请日：2004-09-09
申请人： Christopher Johnson , David Witty
发明人： Christopher Johnson , David Witty
IPC分类号： A61K31/496 , C07D403/02
CPC分类号： C07D215/40
摘要： This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
摘要翻译： 本发明涉及具有药理活性的新型喹啉化合物，其制备方法，含有它们的组合物及其在治疗CNS和其它病症中的用途。
-
公开(公告)号：US20050124628A1
公开(公告)日：2005-06-09
申请号：US10509078
申请日：2003-03-25
申请人： Mahood Ahmend , Christopher Johnson , Martin Jones , Greor Macdonald , Stephen Moss , Mervyn Thompson , Charles Wade , David Witty
发明人： Mahood Ahmend , Christopher Johnson , Martin Jones , Greor Macdonald , Stephen Moss , Mervyn Thompson , Charles Wade , David Witty
IPC分类号： C07D215/40 , A61K20060101 , A61K31/496 , A61K31/4985 , A61P20060101 , A61P3/04 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/28 , A61P43/00 , C07D20060101 , C07D215/00 , C07D401/04 , C07D487/04 , C07D487/08 , C07D43/02
CPC分类号： C07D487/04 , C07D215/00 , C07D487/08
摘要： The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
摘要翻译： 本发明涉及具有药理学活性的新喹啉化合物，其制备方法，含有它们的组合物及其在治疗CNS和其它疾病中的用途。
-
6.发明申请公开(公告)号：US20070249603A1
公开(公告)日：2007-10-25
申请号：US11569383
申请日：2005-05-19
IPC分类号： A61K31/47 , A61K31/4725 , A61K31/5377 , C07D215/18 , C07D215/36 , C07D413/00
CPC分类号： C07D401/04
摘要： The present invention relates to novel quinoline derivatives such as compounds of the formula (I) which have antagonist potency for the 5-HT6 receptor: and the use of such compounds or pharmaceutical compositions thereof in the treatment of CNS and other disorders.
摘要翻译： 本发明涉及新的喹啉衍生物，例如具有5-HT 6受体拮抗剂效能的式（I）化合物：以及这些化合物或其药物组合物在治疗中的用途 CNS等疾病。
-
7.发明申请Piperazinyl-quinoline derivatives useful for the treatment of cns disorders 失效可用于治疗cns病症的哌嗪基 - 喹啉衍生物公开(公告)号：US20070027139A1
公开(公告)日：2007-02-01
申请号：US10572671
申请日：2004-09-23
申请人： Christopher Johnson , Stephen Moss , David Witty
发明人： Christopher Johnson , Stephen Moss , David Witty
IPC分类号： A61K31/551 , A61K31/496 , C07D403/02
CPC分类号： C07D215/40
摘要： This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
摘要翻译： 本发明涉及具有药理活性的新型喹啉化合物，其制备方法，含有它们的组合物及其在治疗CNS和其它病症中的用途。
-
公开(公告)号：US20050222124A1
公开(公告)日：2005-10-06
申请号：US10504111
申请日：2003-02-13
申请人： Steven Bromidge , David Cooper , Ian Forbes , Andrew Gribble , Christopher Johnson , Andrew Plightfoot , Stephen Moss , Andrew Payne , Shahzad Rahman , David Witty
发明人： Steven Bromidge , David Cooper , Ian Forbes , Andrew Gribble , Christopher Johnson , Andrew Plightfoot , Stephen Moss , Andrew Payne , Shahzad Rahman , David Witty
IPC分类号： A61K31/40 , A61K31/4035 , A61K31/47 , A61K31/472 , A61K31/55 , A61P1/08 , A61P3/04 , A61P15/10 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P43/00 , C07D209/44 , C07D217/02 , C07D217/04 , C07D223/16 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/12 , C07D407/10 , C07D409/10 , C07D409/12 , C07D413/10 , C07D413/12
CPC分类号： C07D223/16 , A61K31/40 , A61K31/47 , A61K31/55 , C07D209/44 , C07D217/02 , C07D217/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要： The invention provides compounds of formula (I) wherein A and B represent the groups —(CH2)m- and —(CH2)n-respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C3-7cycloalkylC1-6alkoxy, —(CH2)pC3-6cycloalkyl, —(CH2)pC3-6cycloalkyloxy, —COC1-6alkyl, —SO2C1-6alkyl, —SOC1-6alkyl, —S—C1-6alkyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, —CO2C1-6alkyl, —CO2NR7R8, —SO2NR7R8, C1-6alkylsulfonamido, C1-6alkylsulfonamidoC1-6alkyl, —(CH2)pNR7R8, C1-6alkylamidoC1-6alkyl, —(CH2)pNR7COR8, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, aroylC1-6alkyl, arylC1-6alkanoyl, —SO2NR7R8, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl, or a group CONR7R8 or SO2NR7R8 wherein R7 and R8 together may be fused to form a 5- 7-membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom; R3 represents hydrogen or C1-6alkyl; Ar represents optionally substituted phenyl or optionally substituted monocyclic heteroaryl group; R4 represents optionally substituted aryl or optionally substituted heteroaryl; R7 and R8 each independently represent hydrogen, C1-6alkyl or together form a 5- to 7-membered heterocyclic ring; Z represents a bond, an oxygen atom or C1-6alkyl; Y represents hydrogen or C1-6alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q represents an integer from 1 to 3; r represents an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful in therapy, in particular as antipsychotic agents.
-
公开(公告)号：US20050124626A1
公开(公告)日：2005-06-09
申请号：US10509077
申请日：2003-03-25
申请人： Christopher Johnson , Gregor Macdonald , Darren Mitchell , Stephen Moss , Mervyn Thompson , David Witty
发明人： Christopher Johnson , Gregor Macdonald , Darren Mitchell , Stephen Moss , Mervyn Thompson , David Witty
IPC分类号： A61K31/496 , A61P3/04 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , C07D215/40 , C07D215/46 , C07D471/04 , C07D43/02
CPC分类号： C07D471/04 , C07D215/40 , C07D215/46
摘要： The present invention relates to novel quinoline and aza indole compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
摘要翻译： 本发明涉及具有药理活性的新型喹啉和氮杂吲哚化合物，其制备方法，含有它们的组合物及其在治疗CNS和其它疾病中的用途。
-
公开(公告)号：US10274315B2
公开(公告)日：2019-04-30
申请号：US15347095
申请日：2016-11-09
IPC分类号： G01B11/275 , B62D17/00
摘要： A vehicle wheel alignment rack is described herein that includes at least one laser and a target. The laser is removably coupled to a wheel of a vehicle. The target corresponds to the laser and is disposed at an opposite end of the vehicle from the laser. The target is directly and removably coupled to a frame of the vehicle such that the target is aligned with the frame at a known angle. The wheel is aligned to the frame by comparing the known angle to an expected and actual position on the target where a beam of light from the laser strikes the target. Some embodiments of the claimed invention include at least a second laser and a second target similarly disposed. Various means of coupling the target or targets to the frame are also disclosed herein.
-
-
-
-
-
-
-
-
-
搜索结果
137 条记录 (耗时 0.021 秒)
